Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$60.45 - $84.26 $27.8 Million - $38.8 Million
-460,000 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$58.19 - $91.37 $2.04 Million - $3.2 Million
35,000 Added 8.24%
460,000 $30.4 Million
Q4 2020

Feb 16, 2021

BUY
$20.19 - $84.93 $8.58 Million - $36.1 Million
425,000 New
425,000 $36.1 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Consonance Capital Management LP Portfolio

Follow Consonance Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Consonance Capital Management LP with notifications on news.